← Leaderboards
Doo Yeon Kim
Massachusetts General Hospital
$15,004,054
Attributed
$24,847,687
Total exposure
10
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.1M · FY2008–25$5M$3.8M$2.5M$1.3M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$24,847,687 · 10
By mechanism
R01$16,667,938 · 6
U19$5,648,300 · 2
RF1$2,119,500 · 1
R21$411,949 · 1
Top collaborators
- Rudolph Emile Tanzi13 shared
- Winston Alexander Hide8 shared
- Stephen Tc Wong5 shared
- Frank J. Slack3 shared
- Mehdi Jorfi2 shared
- Joseph Park2 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Keith W Miller$21,650,712
- Jing Zhou$20,912,829
- Stephen C. Cannon$14,616,444
- Zhongcong Xie$19,705,169
- Daniel S Kohane$17,057,196
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposPathway InteractionsNeuronsS DiseaseBrainPharmaceutical PreparationsS Disease ModelCell Model3-DimensionalMolecularAffectCellsNeurogliaNeuroinflammationNerve DegenerationS Disease PathologyGenesNeurofibrillary TanglesDementiaNeuron LossMicrogliaPhenotypeAstrocytesPathogenicity
Grant awards (33)
Protective factors and mechanisms$1,067,756
U19 · FY2025 · AG · contact PI
Non-coding RNAs in resilience to Alzheimerâs Disease$827,394
R01 · FY2025 · AG
Systematic modeling and prediction of cell-type-specific and spatiotemporal crosstalk pathways in Alzheimer's Disease$774,987
R01 · FY2025 · AG
Studying the pathogenic roles of human CD8+ T cells in Alzheimer's disease using a 3D human Peripheral immune Chip.$673,258
R01 · FY2025 · AG · contact PI
Protective factors and mechanisms$1,039,471
U19 · FY2024 · AG · contact PI
Non-coding RNAs in resilience to Alzheimerâs Disease$844,278
R01 · FY2024 · AG
Systematic modeling and prediction of cell-type-specific and spatiotemporal crosstalk pathways in Alzheimer's Disease$790,802
R01 · FY2024 · AG
Studying the pathogenic roles of human CD8+ T cells in Alzheimer's disease using a 3D human Peripheral immune Chip.$688,000
R01 · FY2024 · AG · contact PI
Protective factors and mechanisms$1,026,777
U19 · FY2023 · AG · contact PI
Non-coding RNAs in resilience to Alzheimerâs Disease$862,503
R01 · FY2023 · AG
Systematic modeling and prediction of cell-type-specific and spatiotemporal crosstalk pathways in Alzheimer's Disease$790,802
R01 · FY2023 · AG
The impact of AD-associated genetic variants in 3D human mixed neural-glial models of AD$756,000
R01 · FY2023 · AG
The Alzheimer's Disease Resiliome: Pathway Analysis and Drug Discovery.$653,770
R01 · FY2023 · AG
Protective factors and mechanisms$1,273,857
U19 · FY2022 · AG · contact PI
Systematic modeling and prediction of cell-type-specific and spatiotemporal crosstalk pathways in Alzheimer's Disease$790,802
R01 · FY2022 · AG
The impact of AD-associated genetic variants in 3D human mixed neural-glial models of AD$756,000
R01 · FY2022 · AG
The Alzheimer's Disease Resiliome: Pathway Analysis and Drug Discovery.$656,115
R01 · FY2022 · AG
Protective factors and mechanisms$1,240,439
U19 · FY2021 · AG · contact PI
Systematic modeling and prediction of cell-type-specific and spatiotemporal crosstalk pathways in Alzheimer's Disease$806,177
R01 · FY2021 · AG
The impact of AD-associated genetic variants in 3D human mixed neural-glial models of AD$756,000
R01 · FY2021 · AG
The Alzheimer's Disease Resiliome: Pathway Analysis and Drug Discovery.$658,414
R01 · FY2021 · AG
The impact of AD-associated genetic variants in 3D human mixed neural-glial models of AD$756,000
R01 · FY2020 · AG
The Alzheimer's Disease Resiliome: Pathway Analysis and Drug Discovery.$660,668
R01 · FY2020 · AG
The impact of AD-associated genetic variants in 3D human mixed neural-glial models of AD$749,200
R01 · FY2019 · AG
The Alzheimer's Disease Resiliome: Pathway Analysis and Drug Discovery.$686,190
R01 · FY2019 · AG
Alzheimer's BACE1 inhibition regulates neuronal contactin function$348,205
R01 · FY2018 · AG · contact PI
Alzheimer's BACE1 inhibition regulates neuronal contactin function$348,205
R01 · FY2017 · AG · contact PI
Alzheimer's BACE1 inhibition regulates neuronal contactin function$348,205
R01 · FY2016 · AG · contact PI
Alzheimer's BACE1 inhibition regulates neuronal contactin function$337,758
R01 · FY2015 · AG · contact PI
A novel human 3D neural cell culture system for the characterization of AD genes$2,119,500
RF1 · FY2014 · AG
Alzheimer's BACE1 inhibition regulates neuronal contactin function$348,205
R01 · FY2014 · AG · contact PI
Altered sodium channel metabolism in Alzheimer's disease$187,708
R21 · FY2009 · AG · contact PI
Altered sodium channel metabolism in Alzheimer's disease$224,241
R21 · FY2008 · AG · contact PI